While there were no significant differences in total CD45+ tumor-infiltrated leukocyte (TIL) abundance in tumors across all treatment groups compared to vehicle + IgG, the addition of ICI into copanlisib + PTX increased the frequency of TIL in the TME (p = 0.04) (Figure 2b). The gene discussed is PTPRC; the disease is neoplasm.